Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 10

Results: 22

Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2523, doi. 10.1007/s00262-022-03186-5
By:
- Gockel, Lukas M.;
- Nekipelov, Katrin;
- Ferro, Vito;
- Bendas, Gerd;
- Schlesinger, Martin
Publication type:
Article
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2549, doi. 10.1007/s00262-022-03182-9
By:
- Thibaudin, Marion;
- Limagne, Emeric;
- Hampe, Léa;
- Ballot, Elise;
- Truntzer, Caroline;
- Ghiringhelli, Francois
Publication type:
Article
Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2535, doi. 10.1007/s00262-022-03181-w
By:
- Samad, Abdus;
- Meghla, Nigar Sultana;
- Nain, Zulkar;
- Karpiński, Tomasz M.;
- Rahman, Md. Shahedur
Publication type:
Article
Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2565, doi. 10.1007/s00262-022-03179-4
By:
- Löwenmark, Thyra;
- Li, Xingru;
- Löfgren-Burström, Anna;
- Zingmark, Carl;
- Ling, Agnes;
- Kellgren, Therese G.;
- Larsson, Pär;
- Ljuslinder, Ingrid;
- Wai, Sun Nyunt;
- Edin, Sofia;
- Palmqvist, Richard
Publication type:
Article
Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2469, doi. 10.1007/s00262-022-03178-5
By:
- Kwiecień, Iwona;
- Rutkowska, Elżbieta;
- Raniszewska, Agata;
- Sokołowski, Rafał;
- Bednarek, Joanna;
- Jahnz-Różyk, Karina;
- Rzepecki, Piotr;
- Domagała-Kulawik, Joanna
Publication type:
Article
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2497, doi. 10.1007/s00262-022-03177-6
By:
- Panaampon, Jutatip;
- Kariya, Ryusho;
- Okada, Seiji
Publication type:
Article
The nuclear transportation of PD-L1 and the function in tumor immunity and progression.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2313, doi. 10.1007/s00262-022-03176-7
By:
- Qu, Liyan;
- Jin, Jiakang;
- Lou, Jianan;
- Qian, Chao;
- Lin, Jinti;
- Xu, Ankai;
- Liu, Bing;
- Zhang, Man;
- Tao, Huimin;
- Yu, Wei
Publication type:
Article
Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
Published in:
2022
By:
- Femel, Julia;
- van Hooren, Luuk;
- Herre, Melanie;
- Cedervall, Jessica;
- Saupe, Falk;
- Huijbers, Elisabeth J. M.;
- Verboogen, Danielle R. J.;
- Reichel, Matthias;
- Thijssen, Victor L.;
- Griffioen, Arjan W.;
- Hellman, Lars;
- Dimberg, Anna;
- Olsson, Anna-Karin
Publication type:
Correction Notice
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2511, doi. 10.1007/s00262-022-03173-w
By:
- Zhang, Hongyu;
- Liu, Zilong;
- Wen, Haoyu;
- Guo, Yifan;
- Xu, Fengkai;
- Zhu, Qiaoliang;
- Yuan, Wei;
- Luo, Rongkui;
- Lu, Chunlai;
- Liu, Ronghua;
- Gu, Jie;
- Ge, Di
Publication type:
Article
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2433, doi. 10.1007/s00262-022-03172-x
By:
- Zhu, Guidong;
- Zhang, Junwen;
- Zhang, Qing;
- Jin, Guishan;
- Su, Xiaodong;
- Liu, Sisi;
- Liu, Fusheng
Publication type:
Article
CMTM6 as a master regulator of PD-L1.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2325, doi. 10.1007/s00262-022-03171-y
By:
- Yaseen, Mahmoud Mohammad;
- Abuharfeil, Nizar Mohammad;
- Darmani, Homa
Publication type:
Article
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2421, doi. 10.1007/s00262-022-03170-z
By:
- Sato, Yosuke;
- Casson, Cierra N.;
- Matsuda, Atsushi;
- Kim, James I.;
- Shi, Judy Qiuju;
- Iwasaki, Shinji;
- Chen, Susan;
- Modrell, Brett;
- Chan, Chingkit;
- Tavares, Daniel;
- Austen, Douglas;
- Ida, Koh;
- Tayber, Olga;
- Hein, Pyae;
- Comeau, Robert;
- Lin, Yafang;
- Shaw, Michael H.
Publication type:
Article
Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2405, doi. 10.1007/s00262-022-03169-6
By:
- Shaikh, Fyza Y.;
- Gills, Joell J.;
- Mohammad, Fuad;
- White, James R.;
- Stevens, Courtney M.;
- Ding, Hua;
- Fu, Juan;
- Tam, Ada;
- Blosser, Richard L.;
- Domingue, Jada C.;
- Larman, Tatianna C.;
- Chaft, Jamie E.;
- Spicer, Jonathan D.;
- Reuss, Joshua E.;
- Naidoo, Jarushka;
- Forde, Patrick M.;
- Ganguly, Sudipto;
- Housseau, Franck;
- Pardoll, Drew M.;
- Sears, Cynthia L.
Publication type:
Article
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2371, doi. 10.1007/s00262-022-03160-1
By:
- Zheng, Yulong;
- Mislang, Anna Rachelle Austria;
- Coward, Jermaine;
- Cosman, Rasha;
- Cooper, Adam;
- Underhill, Craig;
- Zhu, Jianqing;
- Xiong, Jianping;
- Jiang, Ou;
- Wang, Hong;
- Xie, Yanru;
- Zhou, Yuefen;
- Jin, Xiaoping;
- Li, Baiyong;
- Wang, Zhongmin Maxwell;
- Kwek, Kon Yew;
- Xia, Dennis;
- Xia, Yu;
- Xu, Nong
Publication type:
Article
Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2449, doi. 10.1007/s00262-022-03167-8
By:
- Qu, Li-Hua;
- Fang, Qian;
- Yin, Tong;
- Yi, Hui-Mei;
- Mei, Guang-Bo;
- Hong, Zi-Zhan;
- Qiu, Xue-Bing;
- Zhou, Rui;
- Dong, Hui-Fen
Publication type:
Article
Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2381, doi. 10.1007/s00262-022-03166-9
By:
- Keber, Corinna U.;
- Derigs, Marcus;
- Schultz, Carolin;
- Wegner, Moritz;
- Lingelbach, Susanne;
- Wischmann, Viktoria;
- Hofmann, Rainer;
- Denkert, Carsten;
- Hegele, Axel;
- Hänze, Jörg
Publication type:
Article
Transient 40 °C-shock potentiates cytotoxic responses of Vδ2+ γδ T cell via HSP70 upregulation.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2391, doi. 10.1007/s00262-022-03164-x
By:
- Lin, Li;
- Chen, Yan;
- Chen, Dan;
- Shu, Junxiang;
- Hu, Yi;
- Yin, Zhinan;
- Wu, Yangzhe
Publication type:
Article
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2301, doi. 10.1007/s00262-022-03163-y
By:
- Ormhøj, Maria;
- Abken, Hinrich;
- Hadrup, Sine R.
Publication type:
Article
Correction to: Functional virus‑specific memory T cells survey glioblastoma.
Published in:
2022
By:
- Ning, Jianfang;
- Gavil, Noah V.;
- Wu, Shaoping;
- Wijeyesinghe, Sathi;
- Weyu, Eyob;
- Ma, Jun;
- Li, Ming;
- Grigore, Florina‑Nicoleta;
- Dhawan, Sanjay;
- Skorput, Alexander G. J.;
- Musial, Shawn C.;
- Chen, Clark C.;
- Masopust, David;
- Rosato, Pamela C.
Publication type:
Correction Notice
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2485, doi. 10.1007/s00262-022-03159-8
By:
- Loeb, David M.;
- Lee, Ji Won;
- Morgenstern, Daniel A.;
- Samson, Yvan;
- Uyttebroeck, Anne;
- Lyu, Chuhl Joo;
- Van Damme, An;
- Nysom, Karsten;
- Macy, Margaret E.;
- Zorzi, Alexandra P.;
- Xiong, Julia;
- Pollert, Petra;
- Joerg, Ingrid;
- Vugmeyster, Yulia;
- Ruisi, Mary;
- Kang, Hyoung Jin
Publication type:
Article
VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2355, doi. 10.1007/s00262-022-03156-x
By:
- Khan, ANM Nazmul H.;
- Emmons, Tiffany R.;
- Magner, William J.;
- Alqassim, Emad;
- Singel, Kelly L.;
- Ricciuti, Jason;
- Eng, Kevin H.;
- Odunsi, Kunle;
- Tomasi, Thomas B.;
- Lee, Kelvin;
- Abrams, Scott I.;
- Mesa, Circe;
- Segal, Brahm H.
Publication type:
Article
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Published in:
Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2341, doi. 10.1007/s00262-022-03143-2
By:
- Song, Peng;
- Li, Wenbin;
- Wu, Xiaoxuan;
- Qian, Zhirong;
- Ying, Jianming;
- Gao, Shugeng;
- He, Jie
Publication type:
Article

Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 10

Tumour cell-activated platelets modulate the immunological activity of CD4<sup>+</sup>, CD8<sup>+</sup>, and NK cells, which is efficiently antagonized by heparin.

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches.

Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer.

Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.

Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

The nuclear transportation of PD-L1 and the function in tumor immunity and progression.

Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.

Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.

Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.

CMTM6 as a master regulator of PD-L1.

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.

Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.

Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.

Transient 40 °C-shock potentiates cytotoxic responses of Vδ2<sup>+</sup> γδ T cell via HSP70 upregulation.

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.

Correction to: Functional virus‑specific memory T cells survey glioblastoma.

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.

VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.